Ridley Corporation Limited provided an update on commercial trials with Novacq that have been completed with three key Australian prawn farm operators. Ridley initiated commercial trials, on profit share arrangements, with three prawn farm operators in late 2017. All operators are existing Ridley prawn feed customers. The objective of the trial was to compare two nutritionally identical steam-pelleted prawn diets on each farm with the exception that one diet contained 5% Novacq and one did not. Both commercial diets were manufactured at the Ridley Narangba mill using Novacq produced at Ridley facilities in Yamba, NSW. Each operator began their trial in commercial sized ponds in January 2018 and harvested in late April/May 2018. The trials were conducted using standard commercial procedures managed by the prawn farm operators, with Ridley personnel inspecting the sites on a regular basis and overseeing the stocking and harvesting processes. Overall, the commercial trials demonstrated a positive response to Novacq, with all three farm operators delivering on average growth rate outcomes in line with previous Novacq disclosed commercial trials. Other significant observations from the trials include: Some operators reported record biomass (determined by growth and survival) harvests per hectare; There was a high degree of variation in the survivability of prawns on the various farms, in both treatments; A low protein Novacq diet was trialled at one farm successfully. This potentially enables Australian farmers to increase their biomass by up to 25% if they are at or reaching maximum nitrogen farming limits set by the EPA; Two operators intend to purchase NovacqTM in 2018/19. The third operator is restructuring and intends to defer a decision on 2018/19 feed requirements until a new owner is in place.